Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2022-10-11 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
2022-085
Regulatory Filings Classification · 90% confidence The document is a public announcement by Beijing Northland Biotech Co., Ltd. about the company's reception of institutional investor research on October 11, 2022. It details the questions asked by investors and the company's responses regarding clinical trial progress, patents, and product pipeline. The document is an announcement of an investor meeting or research session rather than a financial report or regulatory filing. It does not contain financial statements, audit information, voting results, or executive changes. It is not a transcript of a call but a summary of investor engagement. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-10-11 Chinese
关于接待机构投资者调研情况的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Northland Biotech Co., Ltd. about the company's reception of institutional investor research on October 11, 2022. It details the questions asked by investors and the company's responses regarding clinical trial progress, patents, and product pipeline. The document is relatively short (1594 characters) and focuses on investor relations and company updates rather than financial statements or regulatory filings. It does not contain financial data, audit information, or voting results. It is not a transcript of a call but a summary of an investor research meeting. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-10-11 Chinese
关于接待机构投资者调研情况的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the reception of institutional investor research and includes detailed Q&A about clinical progress, project updates, and business performance. It is not a full financial report, earnings release, or regulatory filing. It is a disclosure of investor relations activity and company responses to investor questions, which is typical of a Regulatory Filings (RNS) category as it does not fit other specific categories like earnings release or management report. The document length is short (2001 characters) and it is an announcement rather than a full report.
2022-08-25 Chinese
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the storage and actual use of raised funds (募集资金存放与实际使用情况的专项报告). It details the company's fundraising activities, including the issuance of new shares, the amount raised, the use of funds, and compliance with regulatory requirements. It includes specific financial figures related to the raised funds, their management, and usage progress. The document also references audit reports on the capital raised and the regulatory approval for the fundraising. The content is focused on the management and use of capital raised through equity issuance, which aligns with a Capital/Financing Update. The document is not an annual or interim report, nor is it a simple announcement or certification. It is a detailed report on fundraising and capital usage, fitting the Capital/Financing Update (CAP) category.
2022-08-18 Chinese
第五届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Northland Biotech Co., Ltd. regarding the review and approval of the company's 2022 semi-annual report and related fundraising usage reports. It includes voting results and supervisory opinions on these reports but does not contain the actual financial statements or detailed financial data itself. The document references the actual semi-annual report and other reports published on the Beijing Stock Exchange website, indicating this document is a meeting resolution or announcement rather than the report itself. The document length is 2755 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Regulatory Filings (RNS) as it is a formal announcement of supervisory board resolutions and opinions on reports rather than the reports themselves.
2022-08-18 Chinese
使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's use of idle raised funds for cash management. It details the fundraising amounts, usage progress, investment products, decision-making process, risk control, and opinions from independent directors, supervisors, and the sponsoring institution. The document does not contain financial statements or comprehensive financial data but is a regulatory disclosure about the use of funds raised through equity issuance. It is not an annual or interim report, earnings release, or audit report. The document is a regulatory announcement about capital usage and management, fitting best under Capital/Financing Update (CAP). The document length is 3394 characters, which is relatively short but contains substantive information about capital usage rather than just a report publication announcement or a simple notification. Therefore, the classification is CAP with high confidence.
2022-08-18 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.